Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study

Table 2 Alterations of the gut microbiota between CN− and CN+ using GLM

	CN− (n = 34)	CN+ (n = 32)	F _{(1, 60)}	P value
p_Bacteroidetes	40.01 ± 16.14	50.76 ± 18.25	7.103	0.010
p_Firmicutes	51.85 ± 16.08	39.71 ± 17.26	7.768	0.007
c_Bacteroidia	40.00 ± 16.15	50.76 ± 18.25	7.109	0.010
c_Clostridia	42.93 ± 15.01	32.26 ± 16.71	5.992	0.017
c_Deltaproteobacteria	0.39 ± 0.51	0.15 ± 0.25	4.472	0.039
o_Bacteroidales	40.00 ± 16.15	50.76 ± 18.25	7.109	0.010
o_Clostridiales	42.93 ± 15.01	32.26 ± 16.71	5.992	0.017
o_Desulfovibrionales	0.39 ± 0.51	0.15 ± 0.25	4.472	0.039
f_Lachnospiraceae	21.92 ± 9.50	16.33 ± 7.19	6.096	0.016
f_Ruminococcaceae	18.86 ± 11.79	12.93 ± 11.82	3.491	0.067
f_Desulfovibrionaceae	0.39 ± 0.51	0.15 ± 0.25	4.472	0.039
g_Bilophila	0.29 ± 0.50	0.13 ± 0.24	1.863	0.177
g_Faecalibacterium	11.41 ± 8.65	7.08 ± 7.99	4.008	0.050

Statistical analysis was conducted using GLM, with age, sex, BMI, and APOE as possible confounding factors
Abbreviations: GLM general linear model, CN− amyloid-β-negative cognitively normal participants, CN+ amyloid-β-positive cognitively normal participants, CI cognitive impairment, p phylum, c class, o order, f family, g genus

ISSN: 1758-9193